Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ULREA-PVS-NP is an intravenous nanoparticle formulation of pitavastatin encapsulated in poly(lactic-co-glycolic acid) (PLGA), developed by researchers at Kyushu University. This therapeutic candidate is designed to treat retinitis pigmentosa (RP), a rare inherited retinal degenerative disease characterized by progressive visual field loss. The formulation utilizes PLGA nanoparticles to deliver pitavastatin, an HMG-CoA reductase inhibitor, to target and suppress the activity of inflammatory monocytes and macrophages in the retina. By modulating these inflammatory pathways, ULREA-PVS-NP aims to prevent photoreceptor degeneration and slow the progression of vision loss. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in patients with RP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ULREA-PVS-NP.